Patients with high-risk localized prostate cancer have a poor prognosis, and appropriate treatments are therefore imperative. Herein, the authors present the current clinical evidence of the benefit of neoadjuvant and adjuvant systemic therapies for the treatment of these patients.
- Géraldine Pignot
- Denis Maillet
- Delphine Borchiellini